Novo CEO faces investor grilling after obesity drug disappointments

Novo CEO faces investor grilling after obesity drug disappointments | News24

Novo CEO faces investor grilling after obesity drug disappointments

Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!

Loading, please wait…
0:00Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one country after the other.
Fiordaliso/Getty Images

Read this for free
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
Next on News24
Nedbank flex: Home loans up, deposits climbing – and hunting big-game corporate clients too

description
username
Currencies
Commodities
Jse Indexes
Rand – Dollar
16.37
+0.1%
Rand – Pound
22.04
+0.0%
Rand – Euro
18.89
+0.0%
Rand – Aus dollar
11.53
+0.1%
Rand – Yen
0.10
-0.0%
Platinum
1,785.10
+2.2%
Palladium
1,392.00
+3.2%
Gold
4,162.73
+2.1%
Silver
61.61
+3.5%
Brent Crude
79.36
-5.6%
Top 40
107,163
+0.9%
ALSI
115,257
+0.9%
RESI 10
115,756
+3.1%
INDI 25
132,576
+0.2%
FINI 15
26,972
-0.4%
All JSE data delayed by at least 15 minutes
Buying a drone? Here are the rules in SA

31 Jul

Why I was wrong about the DJI Neo 2

30 Jul

TV buying guide 2026: Everything you need to know

29 Jul

<a href="https://allthat.news24.com/review/health-fitness/garmin-cirqa-smart-band-serious-fitness-tracking-without-the-expensive-watch-or-monthly-subscription/” rel=”nofollow noopener” target=”_blank”>Garmin Cirqa Smart Band: Serious fitness tracking without the expensive watch or…